scispace - formally typeset
K

Keyhan Mohammadi

Researcher at Tehran University of Medical Sciences

Publications -  18
Citations -  615

Keyhan Mohammadi is an academic researcher from Tehran University of Medical Sciences. The author has contributed to research in topics: Medicine & Randomized controlled trial. The author has an hindex of 4, co-authored 11 publications receiving 149 citations.

Papers
More filters
Journal ArticleDOI

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.

Inspiration Investigators, +63 more
- 27 Apr 2021 - 
TL;DR: In this paper, the authors evaluated the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU).
Journal ArticleDOI

Recent Advances in the Development of Smart and Active Biodegradable Packaging Materials

TL;DR: In this paper, the authors reviewed recent advances in the development of active and smart biodegradable packaging materials in the food industry, including dairy, meat, fish, fruit and vegetable products.
Journal ArticleDOI

Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.

Behnood Bikdeli, +64 more
TL;DR: In this article, the authors report the final (90-day) results of the Intermediate versus Standard-dose Prophylactic anticoagulation In cRitically-ill pATIents with COVID-19: An opeN label randomized controlled trial (INSPIRATION) study.
Journal ArticleDOI

Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

TL;DR: The efficacy of statins to reduce the concentrations of CRP and hs-CRP in patients with different types of CVDs was showed, including high-intensity statin treatment and the duration of treatment longer than 10 weeks.
Journal ArticleDOI

Recent progress in the application of plant-based colloidal drug delivery systems in the pharmaceutical sciences.

TL;DR: The potential for utilizing plant-derived components, such as plant proteins, polysaccharides, lipids, and phospholipids, to create targeted drug delivery systems has been demonstrated in recent years as discussed by the authors .